Ixico wins $1.5m contract for neurodegenerative study

Brain health company Ixico has won a $1.5m contract from a pharmaceutical for its imaging clinical trial technology and services.

The contract with an existing customer will see the company supply services for a phase two clinical trial of patients in the early stages of progressive supranuclear palsy, a Parkinson's-like neurodegenerative condition caused by the premature loss of nerve cells in certain parts of the brain, with the study is expected to complete in 2020 and possibly extended.

AIM-listed IXICO will collect, manage and analyse MRI scans from over 90 international imaging centres using its TrialTracker technology, which has been modified for quantifying drug effects on patients with progressive supranuclear palsy.

Ixico chief executive Giulio Cerroni said: "This contract further demonstrates existing customers' endorsement of Ixico's ability to provide compliant delivery of quality data and trustworthy results, and cements our position as a valued partner to the pharmaceutical industry in the drug development process."